Abnova offers comprehensive custom services dedicated to studying and validating the mRNA nanoparticle carrier in both in vitro and in vivo models. These services are specifically designed to provide expression, functional, and efficacy results for vaccine development, protein replacement, immunotherapy, cell therapy, and gene editing studies.
In Vitro Study Service
Abnova utilizes molecular biology and cellular techniques to assess the mRNA nanoparticle carrier. Our evaluation involves qualification and quantification of target gene expression and function including qPCR, sandwich ELISA, competitive assay, western blot, flow cytometry, enzyme-linked immunospot (ELISPOT), eGFP reporter, neutralization, and cytotoxicity assays.
In Vivo Study Service
Abnova relies on immunohistochemistry to study mRNA nanoparticle carrier expression, firefly and Gaussian luciferase reporters to assess tissue distribution, cytokine assay to measure innate and adaptive immune responses, flow cytometry to categorize cell populations, C57BL/6 and BALB/c mice to compare the immunogenicity and efficacy of infection and cancer prophylactic vaccines, C57BL/6 mice for biologic protein production in muscle and liver, and a multitude of immunocompetent syngeneic lung (LLC1), breast (4T1, MMTV-PyMT), colorectal (CT26), liver (BNL) and prostate (TRAMP) cancers, NSG xenograft lung (A549), breast (MCF-7, MDA-MB-231, HCC1937), colorectal (HT29), liver (HepG2), and prostate (LnCaP, DU145, PC3) cancers, and NSG patient-derived xenograft (PDX) models for immunotherapy and cell therapy tumor killing and survival studies.
|
Examples |
|
mRNA Nanoparticle Carrier In Vitro Study |
Comparing Transfection Efficiencies of TransIT® and Lipid K LNP by Two Mixing Methods and Three Cell Types
eGFP mRNA was delivered into BNL, CT26, and BHK21 cells using TransIT® and Lipid K LNP, employing both microfluidic mixing device and hand mixing. Flow cytometry was performed 24 hours post-transfection to measure eGFP expression.
Gene X mRNA was delivered into BNL, CT26, and BHK21 cells using TransIT® and Lipid K LNP, employing both microfluidic mixing device and hand mixing. Flow cytometry was performed 24 hours post-transfection to measure Gene X expression.
|
mRNA Nanoparticle Carrier In Vivo Study |
Bioluminescent Imaging Following Intravenous Administration of Reporter Lipid K LNP in BALB/c Mice
The mouse experiments were conducted in triplicate. Female BALB/c mice were individually injected with 40 μg of Luc-encoding reporter mRNA LNP through the intravenous route. IVIS Spectrum images were captured at 4 and 24 hours post-injection, revealing a significant signal emanating from the liver.
Bioluminescent Imaging Following Intravenous Administration of Reporter Lipid K LNP in BNL Liver Cancer BALB/c Mouse Model
The mouse experiments were conducted in triplicate. Female BALB/c mice were injected with BNL cells via intrahepatic injection. Fifteen days later, 40 μg of Luc-encoding reporter mRNA LNP was administered intravenously. IVIS Spectrum images were captured at 4 and 24 hours post-injection. From each of these time points, one mouse was selected and later sacrificed for further imaging, revealing a significant signal originating from the liver. Afterward, the liver was excised, and the tumors were further isolated and observed for IVIS signal detection, providing additional insight into the intensity of the tumor-specific signals.
CT26 intrasplenic injection colorectal cancer (CRC) liver metastasis BALB/c mouse model and Target X treatment
BALB/c mice were injected with CT26 cells via intrasplenic injection. Three days later, the Gene X RNA vaccine, encapsulated with LNP, was delivered intravenously. Twenty-eight days after treatment, the mice were sacrificed, and spleen and liver weights were measured and compared across untreated, naïve, and four X-treated groups.
- oem@abnova.com
- Global : +886-2-8751-1888 / China: +86-21-51769110